Dracen Pharmaceuticals announces oral presentation at Festival of...
Presentation explores the benefits of broadly targeting glutamine metabolism in cancer and provides a clinical development update on Dracen’s sirpiglenastat (DRP-104)(PRWeb March 09, 2022)Read the full story at https://www.prweb.com/releases/dracen_pharmaceuticals_announces_oral_presentation_at_festival_of_biologics_world_immunotherapy_congress_2022/prweb18544215.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 9, 2022 Category: Pharmaceuticals Source Type: news
Janssen Seeks Approval of a New Indication for IMBRUVICA ® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
BEERSE, BELGIUM, 8 March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for IMBRUVICA® (ibrutinib) in combination with bendamustine and rituximab (BR) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation (ASCT).Ibrutinib is a once-daily Bruton's tyrosine kinase (BTK) inhibitor that is currently approved for patients with MCL who have received at least one prior lin...
Source: Johnson and Johnson - March 8, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Oral health: A ‘difficulty’ in the mouth may be a potential sign of cancer
WHILE less common in the UK, mouth cancer is common globally. Even though it's less common, this does not mean people should not be aware of its symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - March 7, 2022 Category: Consumer Health News Source Type: news
NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2022 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NIDCR News
Science Advances
NIDCR News
NIH & NIDCR Release “Oral Health in America: Advances and Challenges”
In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For mo...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
